SUMMARY Evidence of recent infection with human parvovirus B19 (HPV) was found in two patients with early rheumatoid arthritis (RA) and in four patients with acute inflammatory arthritis (IA). Both of the patients with RA but only one of the four patients with IA carried RA associated haplotypes. No evidence of persistent infection with HPV was found, but evidence of past infection with HPV was significantly more common in patients with RA than in controls. The results confirm the arthritogenic potential of HPV and are consistent with the hypothesis that rheumatoid arthritis may develop in a genetically predisposed patient after an arthritogenic insult such as an HPV infection.
Parvoviruses have recently been suggested as a cause of human joint disease. A parvovirus designated RA-1 was isolated from the synovial tissue of a patient with rheumatoid arthritis and shown to be pathogenic in newborn mice,1 though its involvement in human disease has not been confirmed. A second parvovirus, designated human parvovirus B19 (HPV), which is antigenically distinct from RA-1, has been identified as a cause of acute arthropathy, particularly in women.2 3 The most common clinical manifestation of HPV infection, however, is erythema infectiosum (fifth disease), an exanthematous infection of childhood.4 This is a mild illness without constitutional upset in children, but in adults it is frequently complicated by arthralgia, and joint swelling has been observed in up to 60% of adult cases.5 It is now apparent that HPV infection in adults may present with joint symptoms in the absence of the rash which characterises the infection in children. 2 3 Arthropathy associated with HPV infection usually takes the form of a peripheral, symmetrical polyarthritis of sudden onset. It is relatively benign A common haplotype, B7 BfS C4A*3 C4B*1 DR2, which is negatively associated with RA and may therefore act as protective haplotype against Fig. 1 ). They had only low levels of anti-HPV IgM in the earliest available serum, but this disappeared from subsequent specimens which, together with coincident changes in anti-HPV IgG levels, indicated recent HPV infection. Sera from these patients, however, contained high levels of rheumatoid factor and this is known to give rise to non-specific results when measuring virus specific IgM, though such reactions are thought to be minimised with the 'antibody capture' type assays used in this study.18 Since follow up sera from the same patients and other sera with high titres of RF were negative for anti-HPV IgM and since absorption with insoluble IgG removed RF but not anti-HPV IgM activity from the sera of two patients it is considered that the results obtained with these early rheumatoid sera represent true positive reactions for anti-HPV IgM. The low level of anti-HPV IgM more probably reflects the timing of the specimens, which were collected three and five months after the onset of symptoms. For optimal diagnosis of HPV infection by demonstration of virus specific IgM it is necessary to examine a specimen collected no later than two to three months after onset HPV infection between 30 and 40 years, and it seems likely that a continued gradual increase in the prevalence of anti-HPV IgG occurs with age. It is unlikely, however, that age accounts for the difference between our rheumatoid arthritis patients and controls because when only older subjects are considered (e.g., >40 years) the prevalence of anti-HPV IgG is still significantly higher in patients with rheumatoid arthritis than in controls.
The increased prevalence of anti-HPV IgG in our RA patients is reminiscent of the reported high titres of antibodies to Epstein-Barr virus (EBV) related antigens in RA. The increase in antibodies to EBV has been attributed to a defect in regulatory T lymphocytes, which are specific for EBV, and not to an overall defect in immunoregulatory T cell function.24 A defect in HPV specific T lymphocytes might occur in RA patients and this warrants investigation. In contrast with the persistence of EBV infected cells in most RA patients and normal individuals there were no signs of persistent HPV infection in our RA or IA patients. No virus was detected in synovial fluids and the anti-HPV IgM response did not persist. These findings suggest that while HPV infection may be a triggering factor in rheumatoid arthritis in a genetically predisposed individual the virus is unlikely to have a continuing role in the pathogenesis of the disease. Moreover, the low incidence of HPV infection in our patients and, in a related study,'2 the appearance of RF at widely different times after onset of arthritic symptoms implies that there must be other agents involved in initiating the disease.
